Future Finance Daily

Private markets are built on trust. At Robinhood Ventures, we believe access starts with respecting the companies creating real value. That's why all of our investments to date were directly on the cap table, with issuer approval. That is the kind of access Robinhood Ventures believes in.

The FDA just did something it has never done in its entire history. It greenlit an anti-aging drug. For dogs. Loyal's LOY-002 received FDA confirmation of a "reasonable expectation of effectiveness" for lifespan extension in senior dogs this week. A daily, beef-flavored pill. Dogs 10 years and older. Market target: 2027. That FDA language sounds boring. It isn't. No regulator has ever approved a drug specifically designed to extend lifespan in any species. This is the first time. Ever. The entire longevity biotech sector just got its proof of concept stamped by the highest-quality regulatory agency on the planet. Here's the part that should make you pay attention even if you don't own a dog: dogs age 7x faster than humans and share enough metabolic aging pathways with us that they've become the primary test bed for human longevity science. What works here doesn't stay in the kennel. Your dog gets 1 to 2 extra healthy years. The rest of us get a regulator who just proved anti-aging drugs can clear the bar. That's not a dog story. That's the starting gun.